https://www.prnewswire.com/news-releases/altesa-biosciences-enrolls-first-patient-in-phase-2b-cardinal-clinical-trial-evaluating-vapendavir-as-transformational-treatment-for-patients-with-copd-impacted-by-rhinovirus-the-leading-cause-of-exacerbations-302762079.html?tc=eml_cleartime
Altesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir...
/PRNewswire/ -- Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases including...